APA (7th ed.) Citation

FJ, R., R, R., F, A., D, A., V, L., D, G., . . . F, R. (2023). Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab. Cancer diagnosis & prognosis, 3(1), 44. https://doi.org/10.21873/cdp.10178

Chicago Style (17th ed.) Citation

FJ, Romano, et al. "Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab." Cancer Diagnosis & Prognosis 3, no. 1 (2023): 44. https://doi.org/10.21873/cdp.10178.

MLA (9th ed.) Citation

FJ, Romano, et al. "Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab." Cancer Diagnosis & Prognosis, vol. 3, no. 1, 2023, p. 44, https://doi.org/10.21873/cdp.10178.